Bronchial extrinsic

Examples of these pathophysiologic and pharmacodynamic differences are numerous. Clinical presentation of chronic asthma differs in children and adults. Children present almost exclusively with a reversible extrinsic type of asthma, whereas adults have nonspecific, nonatopic bronchial irritability. This explains the value of adjunctive hyposensitization therapy in the management of pediatric patients with extrinsic asthma. ... 

The promising animal studies with lodoxamide tromethamine led to its investigation in hunan subjects. TVio independent broncho-provocation studies in patients with extrinsic bronchial asthma have been reported. Moreno and LeZotte (24) studied 12 j tients, who had been pretreated randomly with inhaled lodoxamide tromethamine (1.0 mg, 0.1 mg, 0.01 mg) or placebo in a double blind manner, in a standard bronchial challenge. Each of the j tients was treated with each drug dose and placebo in separate settings... 

Clinical Manifestations. The initial manifestations of bronchial asthma can occur at any age. However, the vast majority of extrinsic asthmatics first note symptoms as children or young adults, and those who appear in later decades often have had some earlier manifestation of atopy or allergy. On the other hand, intrinsic asthma generally occurs after the age of 30. Other differences between these two types of asthmatics are noted in Table II. Any individual patient may demonstrate some overlap of these features. For example, the extrinsic asthmatic may be continuously exposed to the specific antigenCs) and, therefore, have symptoms chronically. 

The prognosis in extrinsic asthma is generally excellent, but deaths do occur in otherwise uncomplicated cases. Those who die are usually the more chronic asthmatics. Over 90% will have extensive mucus plugs at autopsy, and hypertrophy of the bronchial smooth muscle is common. Sudden death in young asthmatics also occurs without a good explanation. The prognosis in intrinsic asthma is not as good and is likely similar to that for moderately severe chronic bronchitics. 

The daily excretion of PGF-M was measured in patients who were admitted to hospital with severe exacerbation of extrinsic bronchial asthma. 

It was shown that the PGF metabolite levels were not elevated in extrinsic bronchial asthma. It was also shown that indonethacin decreased the metabolite excretion by inhibition of prostaglandin biosynthesis and not by an effect on metabolism, while prednisolone did not reduce metabolite levels in normal subjects. 

---